CervoMed Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV: $350M estimated peak sales for neflamapimod in dementia with Lewy bodies, 20% probability of Phase 3 success and approval, 2.0x risk-adjusted peak-sales multiple, discounted 6 years to launch at 12%, plus $24.94M net cash; 15.12M diluted shares outstanding.

Reasoning: CervoMed is a pre-revenue clinical-stage biotech whose lead Phase 3 program has not yet started, so value is best captured as net cash plus a heavily risk-adjusted NPV of the DLB program given the earlier stage and binary trial risk relative to more advanced biotech peers.